Advice

In the absence of a submission from the holder of the marketing authorisation.

tolvaptan (Samsca®) is not recommended for use within NHSScotland for the treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice46KB (PDF)

Download

Medicine details

Medicine name:
tolvaptan (Samsca)
SMC ID:
605/10
Indication:
Adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Pharmaceutical company
Otsuka Pharmaceutical Europe
BNF chapter
Endocrine system
Submission type
Non submission
Status
Not recommended
Date advice published
18 January 2010